Natera, Inc. (NASDAQ:NTRA) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC reduced its stake in Natera, Inc. (NASDAQ:NTRAFree Report) by 39.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 4,775 shares of the medical research company’s stock after selling 3,163 shares during the period. SG Americas Securities LLC’s holdings in Natera were worth $756,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its holdings in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares during the period. Quarry LP grew its holdings in shares of Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the period. Covestor Ltd grew its holdings in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the period. GAMMA Investing LLC grew its holdings in shares of Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after purchasing an additional 106 shares during the period. Finally, True Wealth Design LLC acquired a new position in Natera during the 3rd quarter worth about $57,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Natera

In other Natera news, insider Solomon Moshkevich sold 4,858 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $166.59, for a total transaction of $809,294.22. Following the completion of the sale, the insider now owns 114,912 shares in the company, valued at approximately $19,143,190.08. The trade was a 4.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Roelof Botha sold 87,473 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the completion of the sale, the director now owns 1,224,787 shares of the company’s stock, valued at approximately $207,135,977.44. This represents a 6.67 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 241,680 shares of company stock valued at $40,102,873. 7.60% of the stock is currently owned by corporate insiders.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $168.22 on Thursday. Natera, Inc. has a fifty-two week low of $64.74 and a fifty-two week high of $183.00. The business has a 50-day moving average of $166.56 and a two-hundred day moving average of $137.43. The stock has a market capitalization of $22.21 billion, a P/E ratio of -95.58 and a beta of 1.65. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRAGet Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same period in the previous year, the company posted ($0.95) earnings per share. The firm’s revenue for the quarter was up 63.9% on a year-over-year basis. On average, equities research analysts predict that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. TD Cowen increased their target price on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Piper Sandler raised their target price on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. Leerink Partners raised their target price on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Barclays started coverage on Natera in a research note on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price target on the stock. Finally, Craig Hallum lifted their target price on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $165.88.

Read Our Latest Report on NTRA

Natera Company Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

See Also

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRAFree Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.